Targeted brain-artery drug added to standard treatment for new GBM
Part of Brain & nervous system, Cancer clinical trials.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have a confirmed diagnosis of GBM with specific tumor features (not certain other brain tumor types)
- You can do daily activities fairly well (Karnofsky score 70% or higher)
- You have not started chemotherapy or radiation yet for your GBM diagnosis
- You must be able to have MRI scans and enough recent blood-test and liver/kidney function results
- Women who could become pregnant must have a negative pregnancy test and use reliable birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
This Phase 1/2 study tests whether giving cetuximab directly into the artery that feeds the brain tumor can help people with newly diagnosed glioblastoma. It aims to target the tumor more precisely while checking safety and early signs of benefit.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This study combines a focused ultrasound device (NaviFUS) with a drug called bevacizumab to treat glioblastoma that has come back after standard treatment. The combination may help the drug reach the tumor better and improve treatment response.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.